Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592906 | 0.86 | TSHR (0.52) | TRPA1TSHRALDH1A1 | |
| SCHEMBL11675463 | 0.77 | CHRNB2 (0.45) | CHRNB2CHRNA4CYP3A4TAAR1HSD17B10 | |
| SCHEMBL1193245 | 0.74 | CHRNB2 (0.42) | CHRNB2CHRNA4CYP3A4TAAR1HSD17B10 | |
| SCHEMBL954845 | 0.74 | PTGS2 (0.48) | CHRNB2CHRNA4TRPA1TSHRACP3 | |
| SCHEMBL29261466 | 0.74 | CHRNB2 (0.42) | CHRNB2CHRNA4CYP3A4TAAR1HSD17B10 | |
| SCHEMBL8019014 | 0.74 | TSHR (0.75) | CHRNB2CHRNA4CYP3A4TRPA1TSHR | |
| SCHEMBL8018943 | 0.73 | ALDH1A1 (0.42) | TDP1ALDH1A1 | |
| SCHEMBL7952407 | 0.73 | LMNA (0.46) | TDP1ALDH1A1 | |
| SCHEMBL4559442 | 0.71 | PTGS2 (0.46) | CHRNB2CHRNA4TRPA1TSHRACP3 | |
| SCHEMBL11878426 | 0.71 | PTGS2 (0.46) | CHRNB2CHRNA4TRPA1TSHRACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105622580-B | Benzimidazole as prolyl hydroxylase inhibitors | 詹森药业有限公司 | 2019-06-21 | — | — | CN | claimed |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-02 | — | — | US | claimed |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | claimed |
| CN-105622580-A | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV | 2016-06-01 | — | — | CN | claimed |
| CN-102076680-B | Benzimidazoles as Prolyl Hydroxylase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-02 | — | — | CN | claimed |
| US-9073923-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-07 | — | — | US | claimed |
| EP-2294066-B9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-11 | — | — | EP | claimed |
| US-8865713-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | claimed |
| US-20140256722-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | claimed |
| EP-2294066-B1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | claimed |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-01-02 | — | — | US | claimed |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | claimed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | CHRNB2 4844/4885CHRNA4 4804/4885CYP3A4 104/4885 |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | CHRNB2 4839/4885CHRNA4 4811/4885CYP3A4 115/4885 |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | CHRNB2 4839/4885CHRNA4 4811/4885CYP3A4 115/4885 |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | CHRNB2 4839/4885CHRNA4 4811/4885CYP3A4 115/4885 |
| US-20140256722-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | CHRNB2 4839/4885CHRNA4 4811/4885CYP3A4 115/4885 |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | HIF1AN, CXCL12, HIF1A | CHRNB2 4556/4885CHRNA4 4624/4885CYP3A4 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.